Morosini Deborah 4
4 · Prelude Therapeutics Inc · Filed Apr 30, 2021
Insider Transaction Report
Form 4
Morosini Deborah
EVP, Chief of Clinical Affairs
Transactions
- Exercise/Conversion
Common Stock
2021-04-29$1.89/sh+3,223$6,091→ 3,667 total - Sale
Common Stock
2021-04-29$40.29/sh−3,223$129,853→ 444 total - Exercise/Conversion
Employee Stock Option (right to buy)
2021-04-29−3,223→ 4,323 totalExercise: $1.89Exp: 2030-03-26→ Common Stock (3,223 underlying)
Footnotes (3)
- [F1]The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.02 to $41.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F3]This option is fully vested.